Resistance to treatment in CML - Chronic myeloid leukemia

ARTICLES

Navigating Drug Resistance in Chronic Myelocytic Leukemia
October 13, 2022,  Pharmacy Times

Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study
September 2022, ScienceDirect

Treatment Optimization Efforts Seek to Overcome Resistance in Advanced CML
April 15, 2022, OncLive

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
January 5, 2022,  Dovepress

Resistant Chronic Myeloid Leukemia: Starting Over Again
July 2020, Conquer the patient voice

New combination treatment may overcome drug resistance in blood cancers
May 19, 2020, The University of British Columbia
​
Researchers find drug-resistant gene for Gleevec
April 23, 2019,  Korea Biomedical Review

Response and Resistance to BCR-ABL1-Targeted Therapies
April 13, 2020,  Cancer Cell

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
April 7, 2020, PubMed

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
April 2019, Leukemia

OSU Research Paves Way for New Source for Leukemia Drug
March 20, 2019, The Skammer

The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years
September 2017, Indian J Med Paediatr Oncol. 

​The importance of mutational analysis in chronic myeloid leukemia
November 22, 2016, EMJ

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
February 18, 2016,  Biomarker insights      

Could sticky cells cause drug resistance in chronic blood cancer?
March 11, 2014, Medical Xpress

Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment
October 2011, Hematology/oncology clinics of North America

Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
                                         Modes of access to the website
​
1 - Public access  (strongly recommended)
     On several occasions, the CML patient called CMLer will need a password  to access several modules of the website.  
                  (No registration required - Anonymous access)​
​2 - Reserved access to CMLeukemia private group
     On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
​                  (Member password required and registration required).